<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02443961</url>
  </required_header>
  <id_info>
    <org_study_id>PULMESCEL-1</org_study_id>
    <nct_id>NCT02443961</nct_id>
  </id_info>
  <brief_title>Mesenchymal Stem Cell Therapy for Bronchopulmonary Dysplasia in Preterm Babies</brief_title>
  <official_title>Clinical Trial: Security and Feasibility of Mesenchymal Stem Cell Therapy in Treatment and Prevention of Bronchopulmonary Dysplasia in Preterm Babies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto de Salud Carlos III</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fundación de Ayuda a la Investigación sobre la Hipertensión pulmonar</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bronchopulmonary Dysplasia (BPD) is the most frequent disease related to a premature birth,
      15-50% of very low birth newborns (&lt;1500 gr.) will develop BPD. The prevalence of BPD is
      increasing due to the advances in neonatology, with a rise in the survival of smaller and
      more premature babies. The etiology of BPD is multifactorial, in which oxygen, maternal
      chorioamnionitis, insufficient pulmonary maturation etc. have an important role. These
      factors lead to a pathological development of the lung and pulmonary vessels, developing
      secondary Pulmonary Hypertension (PH). Nowadays there is no efficient treatment; this
      generates a important sanitary burden and a decrease in life quality. Multiple experimental
      models in mice have studied Mesenchymal Stem Cell (MSC) therapy as prevention of BPD, also
      recently some clinical trials have tried this therapy on premature newborns with promising
      results. Hypothesis: MSC therapy in patients at high risk of BPD prevents pulmonary lesions.
      Methods: The investigators have designed a clinical trial to evaluate the feasibility and
      security of MSC therapy in patients at high risk of developing BPD.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2018</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility and security of MSC therapy in very low birth weight preterm babies at risk of developing bronchopulmonary dysplasia (Number of participants with adverse events)</measure>
    <time_frame>24 months</time_frame>
    <description>Number of participants with adverse events as a measure of safety and tolerability</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biomarker analysis (IL-1beta, IL-6, IP-10, INF-gamma, TGF beta, NLRP3, RAGE, HMGB1, VEGFA, GREMLIN1, sVEGFR1, IGF, ENDOTHELIN-1, SMPD-1, SP-D, SMPD3.</measure>
    <time_frame>24 months</time_frame>
    <description>biomarkers will be measured in pg/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the echocardiographic parameters related with PH and preterm birth, in patients treated with MSC (Number of participants with echocardiographic adverse events)</measure>
    <time_frame>24 months</time_frame>
    <description>Flattening of the interventricular septum will be the main parameter (tipe I, I-II, II, II-III OR III)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of BPD and PH in very low birth weight babies treated with MSC</measure>
    <time_frame>24 months</time_frame>
    <description>Diagnosed at 36 weeks of postmenstrual age</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Bronchopulmonary Dysplasia</condition>
  <arm_group>
    <arm_group_label>Mesenchymal Stem Cell (MSC) therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>There will only be one treatment arm to evaluate the security of the treatment with MSC.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mesenchymal Stem Cell (MSC) therapy</intervention_name>
    <description>3 doses of 5 million MSC will be administered</description>
    <arm_group_label>Mesenchymal Stem Cell (MSC) therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Preterm newborns ≤ 28 weeks gestational age

          -  Birth Weight &lt;1250 gr.

          -  Still on of mechanical ventilation FiO2 &gt; 0,3 at day + 14

        Exclusion Criteria:

          -  Other congenital pathology (pulmonary malformations, active pulmonary bleeding, renal
             malformations, CHD, malformative syndromes, chromosomopathies)

          -  Severe neurological lesion.

          -  HIV infection

          -  Cardiovascular instability due to any cause

          -  72 hours after mayor surgery

          -  Necrotizing enterocolitis grades II or higher, according to Bell classification, at
             the time of inclusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>28 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Jesus del Cerro, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRYCIS. Hospital Universitario Ramón y Cajal. Madrid. Spain</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maria Jesús del Cerro, PhD</last_name>
    <phone>34 91 36 8000</phone>
    <email>majecerro@yahoo.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>María Alvarez, MD</last_name>
    <phone>34 9 336 8000</phone>
    <email>mery1812@hotmail.com</email>
  </overall_contact_backup>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2015</study_first_submitted>
  <study_first_submitted_qc>May 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2015</study_first_posted>
  <last_update_submitted>February 6, 2018</last_update_submitted>
  <last_update_submitted_qc>February 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bronchopulmonary dysplasia</keyword>
  <keyword>pulmonary hypertension</keyword>
  <keyword>stem cell therapy</keyword>
  <keyword>mesenchymal stem cells</keyword>
  <keyword>very low weight preterm babies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Bronchopulmonary Dysplasia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

